Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Sanofi announces change in R&D leadership

Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim

Sanofi updates on amcenestrant clinical development program

The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial

USFDA approves Dupixent as first treatment for 12 and older with eosinophilic esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date

Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand

Sanofi and IGM Biosciences team up to commercialise IgM antibody agonists

Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets

Dupixent is a star in Sanofi’s immunology strategy

Dupixent peak sales ambition raised to more than €13 billion

Sanofi announces €300 million collaboration with Blackstone Life Sciences

The investment will accelerate the overall Sarclisa development program

Sanofi and Seagen to jointly develop multiple novel antibody-drug conjugates

Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old